The Systems Biology of Drug Resistance in Cancer group, led by professor Sampsa Hautaniemi, focuses on understanding and finding effective means to overcome drug resistance in cancers. Our approach is to use systems biology, i.e., analyze molecular & clinical data from cancer patients with machine learning and mathematical methods, to identify efficient patient-specific therapeutic targets. Our work is cross-disciplinary and done in close collaboration with researchers from various disciplines, including clinicians, cell biologists and geneticians. The main objective of our research is to obtain hypotheses and predictions that can be tested in wet-lab or in clinical trials and thereby translate medical data into benefits in cancer patient care.
Read more
@HautaniemiLab

Interested in rethinking #ovariancancer? Or how to retain one's sanity in a translational research consortium? Come… twitter.com/i/web/status/1…

Register on 9th of June the latest to our @EU_H2020 project's public webinar on the clinical importance of… twitter.com/i/web/status/1…

We are happy to present a preprint by #JuricaLevatic feat. @msalvadoresf: ➡️"Mutational signatures are markers of d… twitter.com/i/web/status/1…

Save the date and join us for an exiting free webinar on the Clinical Importance of #DrugResistance Mechanisms in… twitter.com/i/web/status/1…